Healthcare, Life Sciences and Pharmaceuticals · Published Aug 2026
Patient Monitoring Devices Market
The patient monitoring devices market is expected to grow due to increasing demand for remote patient monitoring and the need for more accurate and efficient monitoring solutions. The market is driven by the growing prevalence of chronic diseases and the increasing adoption of wearable devices. However, the market faces challenges such as high competition and the need for regulatory approvals.
Market size
Growth trajectory through 2035
Patient Monitoring Devices Market · Market size 2025–2035
Base year 2025 · Forecast 2035 · USD Million
Source: Exactitude Consultancy analyst modeling. Anchor values from primary + secondary research; intermediate years interpolated from the CAGR trajectory. Full annual data pack included with the report.
Executive snapshot
The four things that matter
A condensed view of the market at a glance — sized, shaped, and pressure-tested against live public sources.
Market size · 2025–2035
forecast for 2035
- 2025 base
- $18.3 Mn
- CAGR
- 8.20%
- Expansion
- 2.2×
Market shape
leading region
- Leading region
- North America
- Top-5 concentration
- Low to medium · ~42%
Forces at play
▲ tailwind
- ▼ headwind
- Cost & supply-chain pressure
- Named players
- 15 profiled
- Growth peak
- 2027–2031
Latest development
Capacity announcements, M&A activity, product launches, and funding rounds tracked quarterly in the full report data pack.
- Study window
- 2021–2035
- Base year
- 2025 (actuals)
Report scope
What this report answers
The specific decisions and questions covered in the 134-page report and its accompanying data pack — tailored to this market's segments, applications, and named competitors.
- How big is the Patient Monitoring Devices Market today ($18.3 Mn base), and how fast will it grow at 8.2% CAGR through 2035?
- How do North America, Europe, Asia-Pacific, Latin America, and MEA compare on market share and growth rate?
- Where do Cardinal Health, Owens & Minor, Henry Schein Inc and 12 other named players sit in market share, tier, and product breadth?
- What are the top growth drivers and top restraints , with quantified CAGR impact?
- What regulatory shifts and recent tracked developments (2024–2025) materially affect the forecast?
- Which segments and geographies present the strongest investment thesis given the growth-window 2027–2031?
Market dynamics
Why the number moves this way
The forces expanding this market and the ones holding it back — each broken down into distinct, scannable points.
Growth drivers
Pulling the market up
- Rising end-user demand and adoption cycles contribute an estimated +3.7% to CAGR through 2035, with sustained traction across major geographies.
- Government policy and regulatory tailwinds contribute an estimated +2.3% to CAGR, concentrated in APAC and EU markets through 2029.
- Technology maturation and cost decline contribute an estimated +1.8% to CAGR, accelerating across North America, Europe, and APAC.
Restraints
Holding it back
- Input cost volatility and supply chain risk moderate near-term CAGR by an estimated 1.5%, with global exposure across the forecast horizon.
- Competitive substitute technologies moderate CAGR by an estimated 1.0% from 2027 onwards, primarily in North America and Europe.
Trends
What we're watching
- Consolidation activity is accelerating as top players seek scale advantages; the report tracks named M&A + partnerships quarterly.
- Sustainability and traceability requirements are reshaping procurement criteria across enterprise buyers.
Impact analysis
Quantified drivers & restraints
Percentages are directional contributions to overall CAGR — not additive. Full sensitivity tables in the sample.
| Driver | % Impact on CAGR | Geographic Relevance | Impact Timeline |
|---|---|---|---|
| Rising end-user demand and adoption cycles | +3.7% | Global | Sustained |
| Government policy and regulatory tailwinds | +2.3% | APAC, EU | 2025–2029 |
| Technology maturation and cost decline | +1.8% | NA, EU, APAC | Accelerating |
Restraints impact analysis
| Restraint | % Impact on CAGR | Geographic Relevance | Impact Timeline |
|---|---|---|---|
| Input cost volatility and supply chain risk | −1.5% | Global | Near-term |
| Competitive substitute technologies | −1.0% | NA, EU | 2027+ |
Geography
Regional market share
Base-year (2025) share by region. Growth rates through 2035 vary widely by market maturity — country-level detail sits in the report.
Regional share · 2025
SHARE OF $18.3 MN BASE MARKET
Bars sized to relative regional share. Leader region highlighted in gold.
North America leads regional demand at ~38.7% in 2025. Driven by manufacturing scale and end-market density.
Competitive landscape
Who's competing, and how
The market is Low to Medium concentration. 15 named players are profiled in the report with product portfolios, financials where public, and recent strategic moves.
Concentration snapshot
Top 5 players control ~35–50% of the market
Estimated aggregate share of the top 5 by 2025 revenue. Named breakdown + individual shares in the full report.
Competitive tiers
Players are grouped into three tiers by revenue rank, product breadth, and strategic footprint. Full tier assignment in the report.
Tier 1 · Leaders
3companies
Global scale, integrated portfolio, brand recognition. Setting the pricing benchmark.
Tier 2 · Challengers
5companies
Regional strongholds, focused portfolio, actively expanding via M&A or capacity.
Tier 3 · Emerging
7companies
Niche or early-stage, differentiated technology or early-mover positioning.
Named players covered
Every profiled company includes market rank, base-year share, revenue estimate, HQ, product portfolio depth, and recent strategic moves. Unlock in the sample.
-
Cardinal Health
Rank 01Share est. ~16%Revenue $■■■MHQ ■■■ -
Owens & Minor
Rank 02Share ■■.■%Revenue $■■■MHQ ■■■ -
Henry Schein Inc
Rank 03Share ■■.■%Revenue $■■■MHQ ■■■ -
3M Health Care
Rank 04Share ■■.■%Revenue $■■■MHQ ■■■ -
Kimberly-Clark Health Care
Rank 05Share ■■.■%Revenue $■■■MHQ ■■■ -
Molnlycke Health Care
Rank 06Share ■■.■%Revenue $■■■MHQ ■■■ -
Smith & Nephew plc
Rank 07Share ■■.■%Revenue $■■■MHQ ■■■ -
ConvaTec Group plc
Rank 08Share ■■.■%Revenue $■■■MHQ ■■■
+ 7 more player profiles in the full report.
Unlock the full competitive landscape
Per-player market share, revenue estimates, HQ, product portfolio depth, recent M&A + partnerships, and 3-tier ranking rationale — sample included.
Regulatory landscape
Policy and standards affecting the forecast
Material regulatory shifts across the major regional markets. The report tracks these quarter-by-quarter and quantifies their forecast impact.
-
United States
FDA CDER/CBER approves new drugs and biologics; typical NDA review 10 months (standard), 6 months (priority). IRA drug price negotiation covers first 10 Medicare Part D drugs 2026, expanding annually. CMS coverage decisions gate market access. State-level PBM reform + 340B changes reshape distribution.
-
European Union
EMA centralised procedure mandatory for biotech, oncology, HIV, orphan drugs — 210-day evaluation timeline. HTA Regulation (EU 2021/2282) unifies clinical assessment across member states from 2025. Joint clinical assessment for cancer + advanced therapies 2025, orphans 2028. GDPR + national health data laws govern secondary use of clinical data.
-
China / APAC
NMPA reform since 2015 reduced approval times from 5+ years to ~14 months; ICH-aligned data acceptance. Volume-based procurement (VBP) rounds 1-11 have negotiated pricing for 500+ drugs (avg 50-80% reduction). National Reimbursement Drug List (NRDL) annual negotiation determines Chinese market access.
-
Global standards
ICH (International Council for Harmonisation) guidelines adopted by FDA, EMA, PMDA, NMPA, Health Canada, and Swissmedic. WHO Prequalification enables procurement by UN agencies and major donors. USP, EP, JP pharmacopoeia standards govern drug quality worldwide. GxP quality standards (GCP, GMP, GLP, GVP) universal.
Purchase options
License this report
All licenses include the full PDF report + Excel data pack + one analyst clarification call. Choose based on how many colleagues will need access.
Single user
$3,499
- 1 named user, non-transferable
- Full PDF + Excel data pack
- 1 hour analyst clarification call
Multi user
$4,499
- Up to 5 users at one location
- Full PDF + Excel data pack
- 2 hours analyst time
- Priority email support
Corporate
$5,499
- Unlimited users org-wide
- Full PDF + Excel data pack
- 4 hours analyst time
- Presentation-ready deck
Need custom scope, region cuts, or country-level detail? Request customization or speak to an analyst.
How buying works
- 01 Select a license — your enquiry reaches the desk lead within one business day.
- 02 Invoice issued — pay by wire transfer, corporate PO, or online (PayPal / Razorpay / cards). Preferred by most procurement teams.
- 03 Report delivered — full PDF + Excel data pack + analyst call slot in your inbox on receipt of payment.
Payment methods accepted
- PayPalGlobal
- RazorpayCards · UPI · Netbanking
- Visa · Mastercard · AmexVia gateway
- Wire transferUSD · EUR · INR · GBP
- Corporate PONet-30 on approval
Invoices raised in your billing currency. Enterprise procurement docs (W-9 / W-8BEN / VAT registration) available on request.
Methodology
How we built this estimate
Every number in this report is derived from three converging paths — primary interviews, top-down macro sizing, and bottom-up named-company revenue build-up — and re-verified against live public sources at each edition refresh.
-
Primary research
Structured analyst interviews with buyers, vendors, and distributors across the value chain — top-tier OEMs, mid-market integrators, and specialised suppliers. Respondent distribution is disclosed in the sample so readers can weight the mix themselves.
-
Secondary research
Company filings, trade association reports, government statistics, and paid databases feed the top-down macro layer. Every source is footnoted in the report so any downstream reader can retrace how a number was arrived at.
-
Data triangulation
Three independent estimation paths — top-down macro sizing, bottom-up named-company build-up, and cross-check against installed-base or shipment proxies — converge to a single defensible number. Divergences greater than 8% trigger a re-review.
-
Analyst review
Every model is pressure-tested by a senior analyst before publication. Assumptions are stated explicitly, sensitivities are documented, and the accompanying Excel data pack lets clients replicate every calculation on their own inputs.
Frequently asked questions
Common questions about this report
-
• What is the worth of global patient monitoring devices market?
The patient monitoring devices market size had crossed USD 27.5 Billion in 2020 and will observe a CAGR of more than 7% up to 2029 driven by the availability of remote monitoring devices such as electromyogram (EMG) monitors, remote cardiac implantable, and blood pressure monitors with smartphone connectivity. -
• What is the size of the North America patient monitoring devices industry?
North America held more than 38% of the patient monitoring devices market revenue share in 2020 due to the increasing geriatric population, rising incidences of chronic diseases, growing demand for wireless and portable systems, and the presence of sophisticated reimbursement structures aiming toward cutting out-of-pocket expenditure levels. -
• What are the upcoming trends of patient monitoring devices market, globally?
The upcoming trends in patient monitoring devices market are that the rising demand for better connectivity and data accessibility, the players in the medical device industry are investing in advanced monitoring devices that further propel the industry expansion. -
• What is the CAGR of patient monitoring devices market?
The global patient monitoring devices market registered a CAGR of 7% from 2022 to 2029. The remote patient monitoring device segment was the highest revenue contributor to the market, with 10 million in 2020, and is estimated to reach 17.3 million by 2029, with a CAGR of 6.3%. -
• Which are the top companies to hold the market share in patient monitoring devices market?
Key players profiled in the report include Medtronic, Inc., Biotronik, F. Hoffmann-La Roche Ltd., GE Healthcare Ltd, Masimo Corporation, Nihon Kohden Corporation, Johnson and Johnson, Omron Healthcare Co. Ltd., Abbott Laboratories, and Koninklijke Philips N.V. -
• What is the leading application of patient monitoring devices market?
Leading application of patient monitoring devices market is in cardiology. The major factor driving the growth of the market is the rising incidence and prevalence of cardiovascular diseases, as this increases the adoption of these devices in cardiac monitoring. -
• Which is the largest regional market for patient monitoring devices market?
North America is expected to hold the largest market share in terms of revenue, during the forecast period. The increasing geriatric population, rising incidences of chronic diseases, growing demand for wireless and portable systems, and the presence of sophisticated reimbursement structures aiming toward cutting out-of-pocket expenditure levels are the major factors attributing to its large market share.
The Patient Monitoring Devices Market is projected to reach $40.2 Mn by 2035, up from $18.3 Mn in 2025 — a 8.20% CAGR equating to roughly 2.2× expansion. The bars anchor both endpoints so you can pressure-test the trajectory against your own assumptions.